Supernus Pharmaceuticals Inc. (SUPN) is HealthInvest Partners AB’s 4th Largest Position
HealthInvest Partners AB lowered its position in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 27.2% during the second quarter, Holdings Channel reports. The institutional investor owned 657,533 shares of the specialty pharmaceutical company’s stock after selling 246,000 shares during the period. Supernus Pharmaceuticals makes up about 6.1% of HealthInvest Partners AB’s investment portfolio, making the stock its 4th largest position. HealthInvest Partners AB’s holdings in Supernus Pharmaceuticals were worth $13,394,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of SUPN. Bank of Montreal Can purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $199,000. BNP Paribas Arbitrage SA boosted its stake in shares of Supernus Pharmaceuticals by 126.3% in the second quarter. BNP Paribas Arbitrage SA now owns 11,478 shares of the specialty pharmaceutical company’s stock worth $234,000 after buying an additional 6,407 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter worth about $203,000. Louisiana State Employees Retirement System boosted its stake in shares of Supernus Pharmaceuticals by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 15,300 shares of the specialty pharmaceutical company’s stock worth $312,000 after buying an additional 100 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Supernus Pharmaceuticals by 6.0% in the first quarter. Arizona State Retirement System now owns 17,601 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 1,000 shares in the last quarter. Institutional investors own 94.66% of the company’s stock.
Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 3.04% during midday trading on Wednesday, hitting $26.11. The company had a trading volume of 694,508 shares. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 53.29 and a beta of 1.77. Supernus Pharmaceuticals Inc. has a 12-month low of $9.51 and a 12-month high of $26.30. The company’s 50-day moving average price is $22.75 and its 200 day moving average price is $19.21.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.05. The firm earned $50.40 million during the quarter, compared to analyst estimates of $49.67 million. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. During the same quarter last year, the business posted $0.03 EPS. Equities research analysts predict that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, July 6th. Jefferies Group reiterated a “buy” rating and issued a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Northland Securities cut Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target for the company. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price target for the company. in a research note on Monday, July 18th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $24.50.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 3,395 shares of the stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $22.00, for a total value of $74,690.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gregory S. Patrick sold 2,000 shares of the stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now owns 3,616 shares of the company’s stock, valued at approximately $90,400. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by company insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.